Oramed Pharmaceuticals, Inc. (ORMP) is lower by Monday morning, with the stock decreasing -5.91% in pre-market trading to 2.23. ORMP's short-term technical score of 39 indicates that the stock has traded less bullishly over the last month than 61% of stocks on the market. In the Biotechnology industry, which ranks 139 out of 146 industries, the stock ranks higher than 63% of stocks. Oramed Pharmaceuticals, Inc. has fallen 23.30% over the past month, closing at $3.04 on September 11. During this period of time, the stock fell as low as $2.31 and as high as $3.19. ORMP has an average analyst recommendation of Sell. The company has an average price target of $3.65.
ORMP has an Overall Score of 39. Find out what this means to you and get the rest of the rankings on ORMP!